Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

Rimegepant 75 mg for 52 weeks is well tolerated, with no liver safety signals and a sustained reduction in monthly migraine days, a new extension study shows.

Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond ...

Pfizer, on behalf of its wholly-owned subsidiary Biohaven Pharmaceutical Holding Company, has agreed to pay close to $60 million to resolve kickback allegations involving payment to providers.

Pfizer has agreed to pay $59.75 million to settle claims that Biohaven Pharmaceutical Holding Co., which it acquired in 2022, defrauded Medicare and other healthcare programs by paying kickbacks ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for preferential prescriptions.

Pfizer to pay nearly $60M to resolve physician kickback scheme Pfizer, on behalf of its subsidiary Biohaven Pharmaceutical Holding Company, agreed to pay $59,746,277 to resolve allegations that prior ...

In another cautionary tale of kicking all the tires before an acquisition, Pfizer Inc. agreed to a nearly $60 million settlement to resolve a whistleblower’s claims that Biohaven Pharmaceutical ...

Pfizer (PFE) has agreed to pay nearly $60M to resolve allegations that its Biohaven unit paid kickbacks to induce prescriptions for its migraine drug Nurtec ODT. Read more here.

Pfizer Inc's PFE subsidiary Biohaven Ltd BHVN released an updated investor presentation with additional data on the company's BHV-1300 program, a potential competitor to FcRn-targeting ...

As previously reported, Biohaven Ltd. launched post-closing of the Biohaven Pharmaceutical Holding Company Ltd. sale to Pfizer on October 4, 2022, completed a public offering of 28,750,000 ...